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BACKGROUND: Drug effects can be investigated through natural 
variation in the genes for their protein targets. The present study aimed 
to use this approach to explore the potential side effects and repurposing 
potential of antihypertensive drugs, which are among the most commonly 
used medications worldwide.
METHODS: Genetic proxies for the effect of antihypertensive drug 
classes were identified as variants in the genes for the corresponding 
targets that associated with systolic blood pressure at genome-wide 
significance. Mendelian randomization estimates for drug effects 
on coronary heart disease and stroke risk were compared with 
randomized, controlled trial results. Phenome-wide association study 
in the UK Biobank was performed to identify potential side effects and 
repurposing opportunities, with findings investigated in the Vanderbilt 
University biobank (BioVU) and in observational analysis of the UK 
Biobank.
RESULTS: Suitable genetic proxies for angiotensin-converting enzyme 
inhibitors, β-blockers, and calcium channel blockers (CCBs) were 
identified. Mendelian randomization estimates for their effect on coronary 
heart disease and stroke risk, respectively, were comparable to results 
from randomized, controlled trials against placebo. A phenome-wide 
association study in the UK Biobank identified an association of the CCB 
standardized genetic risk score with increased risk of diverticulosis (odds 
ratio, 1.02 per standard deviation increase; 95% CI, 1.01–1.04), with a 
consistent estimate found in BioVU (odds ratio, 1.01; 95% CI, 1.00–1.02). 
Cox regression analysis of drug use in the UK Biobank suggested that this 
association was specific to nondihydropyridine CCBs (hazard ratio 1.49 
considering thiazide diuretic agents as a comparator; 95% CI, 1.04–2.14) 
but not dihydropyridine CCBs (hazard ratio, 1.04; 95% CI, 0.83–1.32).
CONCLUSIONS: Genetic variants can be used to explore the efficacy 
and side effects of antihypertensive medications. The identified potential 
effect of nondihydropyridine CCBs on diverticulosis risk could have clinical 
implications and warrants further investigation.
© 2019 The Authors. Circulation is 
published on behalf of the American 
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Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
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that the original work is properly cited.
Dipender Gill, MD*




Wei-Qi Wei, MD, PhD
Evropi Theodoratou, PhD
Paul Elliott, FMedSci








Use of Genetic Variants Related to 
Antihypertensive Drugs to Inform on 






 http://ahajournals.org by on July 4, 2019
Gill et al Use of Genetic Variants to Inform on Drug Effects














In 2015, the 874 million adults worldwide estimated to have a systolic blood pressure (SBP) of ≥140 mm Hg accounted for 106 deaths per 100 000 and loss of 
143 million disability-adjusted life-years,1 making hy-
pertension a leading cause of mortality and morbidity. 
Blood pressure lowering through lifestyle modification 
or pharmacological treatment can significantly decrease 
cardiovascular risk, with every 10 mm Hg reduction es-
timated to decrease risk of all-cause mortality by 13%.2
The pharmacological treatment of hypertension is 
founded on strong evidence, underpinned by a large 
number of outcome-based randomized, controlled tri-
als (RCTs) that have identified several drug classes to be 
effective for lowering blood pressure.3 However, RCTs 
based on clinical outcomes have limitations4; they are 
largely restricted to older or high-risk patients and have 
a relatively short duration of follow-up, rarely beyond 5 
years.5 Therefore, recommendations for treatment are 
often based on extrapolation of the available evidence, 
with known side effects frequently limited to relative-
ly common outcomes captured in RCTs.6 At the same 
time, particular drug treatments for hypertension may 
have beneficial effects beyond their blood pressure–
lowering properties,6 thus offering potential for repur-
posing. However, observational research used to study 
such opportunities suffers from well-characterized bi-
ases, including confounding by indication.7
With the growing availability of genome-wide asso-
ciation study (GWAS) meta-analyses, it is becoming in-
creasingly feasible to study drug effects by investigating 
genetic variants in the genes of their protein targets, 
as has previously been applied to lipid-lowering drugs.7 
In this study, human genetic variants within genes cor-
responding to the targets of common pharmacological 
agents for hypertension were first identified to serve 
as a proxy for the effects of these treatments. Second, 
the validity of this approach for studying the effects of 
these drugs was investigated by exploring consistency 
in mendelian randomization (MR) estimates for their ef-
fect on coronary heart disease (CHD) and stroke risk 
with corresponding RCT findings. Finally, to offer in-
sight into their adverse effect profiles and repurposing 
potential, phenome-wide association study (PheWAS) 
analyses were undertaken with replication in an exter-
nal dataset, as well as further investigation in observa-
tional analysis of drug use.
METHODS
All supporting data are available within the article, the online-
only Data Supplement, and the web links provided. UK Biobank 
data were accessed through application 236. Relevant ethical 
approval and participant consent were already obtained in all 
studies that contributed data to this work. Statistical analysis 
was undertaken with R version 3.4.1 (The R Foundation for 
Statistical Computing) and Stata 14.2 (StataCorp LP).
Genetic Variant Selection
Common antihypertensive drugs were selected for study 
on the basis of recent consensus guidelines6: angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers, β-blockers (BB), calcium channel blockers (CCB) and 
thiazide diuretic agents. Genes encoding the targets of these 
drugs related to effects on blood pressure were identified 
using the DrugBank database,8 with promoter and enhancer 
regions identified using the GeneHancer database in the 
GeneCards online platform (version 4.7).9 Genetic association 
estimates for SBP were obtained from a GWAS meta-analysis 
of 757 601 individuals with European ancestry drawn from 
the UK Biobank and the International Consortium of Blood 
Pressure GWAS meta-analysis,10 where correction was made 
for antihypertensive medication use by adding 15 mm Hg to 
the SBP of participants receiving medication, with further 
adjustment for body mass index.10 In sensitivity analyses, a 
GWAS of SBP on ≈337 000 white British individuals in the UK 
Biobank was also used, without correction for medication 
use or adjustment for body mass index .11 Genetic variants to 
serve as proxies (ie, instruments) for the effect of lower SBP 
through antihypertensive drug targets were selected as sin-
gle-nucleotide polymorphisms (SNPs) in corresponding genes, 
promoter regions, or enhancers that were associated with 
SBP at genome-wide significance (P<5×10–8) and clumped 
to a linkage disequilibrium (LD) threshold of r2<0.1 using the 
1000G European reference panel. This approach does not 
distinguish between selection of loss-of-function variants 
or those related to gene expression. The R2 and F statistics 
Clinical Perspective
What Is New?
• This work identifies genetic variants that serve as 
proxies for the effect of angiotensin-converting 
enzyme inhibitor, β-blocker, and calcium channel 
blocker antihypertensive drugs.
• Mendelian randomization using the genetic prox-
ies for each respective drug class provides estimates 
consistent with those of randomized, controlled tri-
als against placebo for effects on risk of coronary 
heart disease and stroke.
• Phenome-wide association study identifies diver-
ticulosis as a previously unreported possible side 
effect of calcium channel blockers, with observa-
tional analysis further supporting an association 
between nondihydropyridine calcium channel 
blocker use and increased risk of diverticulosis.
What Are the Clinical Implications?
• Any increase in the risk of diverticulosis related to 
use of nondihydropyridine calcium channel block-
ers could have notable consequences and warrants 
further study.
• No other potential side effects of angiotensin-con-
verting enzyme inhibitors, β-blockers, or calcium 
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were used to estimate the variance in SBP explained and the 
strength of each SNP, respectively.12
Statistical Analysis
Mendelian Randomization
MR uses randomly allocated genetic variants related to an 
exposure of interest to study the effect of that exposure on a 
given outcome. In this study, the exposure of interest was SBP 
lowering through a particular antihypertensive drug class. All 
antihypertensive drug classes for which SNPs were identified 
as proxies using the larger SBP GWAS were taken forward to 
MR analysis investigating their effect on CHD and stroke risk. 
Genetic association estimates for CHD were obtained from the 
CARDIoGRAMplusC4D (Coronary Artery Disease Genome-
wide Replication and Meta-analysis [CARDIOGRAM] plus the 
Coronary Artery Disease [C4D] Genetics) Consortium’s 1000 
Genomes–based transethnic meta-analysis of 60 801 case 
subjects and 123 504 control subjects.13 Estimates for stroke 
risk were obtained from the MEGASTROKE Consortium’s 
transethnic meta-analysis of 67 162 cases of any stroke and 
454 450 control subjects.14 Details for the MR analyses are 
provided in the online-only Data Supplement Methods. To 
allow comparison with RCT results, all MR estimates were 
scaled to the SBP-lowering effect of their respective drug class 
as measured in these RCTs.3
Investigation of Genetic Pleiotropy 
Unrelated to Drug Effect
The MR estimates can be biased if any of the genetic vari-
ants used affect the outcome under consideration through 
a pleiotropic pathway that is independent of the drug effect 
for which they serve as proxies. The PhenoScanner curated 
database of publicly available SNP-phenotype associations 
(accessed on March 30, 2018) was used to explore whether 
any of the selected SNPs or proxies with LD r2>0.8 (using a 
1000G reference panel) were also associated at genome-wide 
significance (P<5×10−8) with traits that may potentially be 
exerting such pleiotropy,15 and any such SNPs were excluded 
in sensitivity analyses. PhenoScanner includes SNP-phenotype 
associations identified in analysis of UK Biobank data.11 
Statistical evaluations of pleiotropy were also incorporated 
where multiple genetic variants were available to serve as 
proxies for the drug effect16 and are detailed in the Methods 
in the online-only Data Supplement.
Phenome-Wide Association Study
The UK Biobank, a prospective study comprising approxi-
mately half a million middle-aged individuals,17 served as 
the cohort for the PheWAS investigating drug side effects 
and repurposing opportunities. The participants provided 
self-reported information, with blood samples collected for 
biochemical tests and genotyping and physical measure-
ments performed as described previously.17 Individuals were 
linked retrospectively and prospectively to the National Health 
Service’s Hospital Episode Statistics database.
PheWAS was restricted to participants of self-reported 
European descent, with random exclusion of 1 participant 
from each pair of relatives based on a kinship coefficient 
>0.0884. For antihypertensive drugs for which genetic vari-
ants were identified to serve as proxies, PLINK was used 
to construct a genetic risk score (GRS) for each individual, 
weighted for the SBP-lowering effect of each participating 
SNP,18 and standardized to have a mean of 0 and an SD of 
1 across all individuals. The 9th and 10th revisions of the 
International Classification of Diseases were used to define 
cases based on inpatient Hospital Episode Statistics data. The 
phecode grouping system was used to align diagnoses used 
in clinical practice with genomic analysis.19 A series of case-
control groups were generated for each phecode, with con-
trol subjects identified as individuals with no record of the 
respective outcome and its related phecodes.19 Analysis was 
performed with logistic regression after adjustment for age, 
sex, and first 4 genetic principal components. Only outcomes 
that had a minimum of 200 cases were considered, to main-
tain sufficient statistical power to identify associations with 
common variants.20 A 5% threshold with the false-discovery 
rate method was used in ascertaining the statistical signifi-
cance of associations, to correct for multiple testing of corre-
lated phenotypes. As for the MR analysis, sensitivity analyses 
were performed using genetic association estimates derived 
from the SBP GWAS that did not correct for medication use 
or adjust for body mass index, and after the exclusion of any 
SNPs with potentially pleiotropic associations at genome-wide 
significance that were identified with PhenoScanner.15
PheWAS associations for noncardiovascular conditions 
were investigated for relation to SBP more generally using a 
permutation-based approach that repeated association analy-
ses 1000 times, with the standardized GRS created on each 
instance using a matched number of randomly sampled SBP-
related SNPs from throughout the genome (ie, associated with 
SBP at genome-wide significance and clumped to LD r2<0.001; 
Table I in the online-only Data Supplement). Compared with 
the investigation of antihypertensive drug targets, a more 
stringent LD threshold was used, because variants for SBP 
were selected from throughout the genome rather than any 
particular locus. The proportion of such permutation analyses 
that have a consistent direction of effect and P value lower 
than in the main PheWAS analysis would serve as an adjusted 
P value of the null hypothesis. Further study of any PheWAS 
associations significant at a false-discovery rate threshold of 
5% for noncardiovascular conditions was also undertaken in 
the Vanderbilt University Biobank (BioVU), for which genetic 
data on ≈50 000 individuals are linked to a deidentified elec-
tronic health record system.21 Similar to the main PheWAS, 
a standardized GRS was constructed, and logistic regres-
sion with the outcome was performed after adjustment for 
age, sex, and first 3 principal components. The analysis was 
restricted to individuals identified as white, with control sub-
jects based on the same exclusions as the main PheWAS. 
Results between the UK Biobank and BioVU analysis were 
pooled by use of a fixed-effects meta-analysis model.
Observational Analysis of Drug Use
PheWAS associations significant at a 5% false-discovery rate 
for noncardiovascular conditions related to any antihyper-
tensive class were further explored in observational analy-
sis of drug use among individuals in the UK Biobank. This 
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and nondihydropyridine CCB subclasses, which was not pos-
sible when using genetic proxies because of overlap in the 
genes for their corresponding protein targets. Cox regression 
analysis was used to compare time to first incident outcome 
between individuals orally taking different antihypertensive 
drug classes at baseline. Individuals who died during the 
follow-up period before a relevant diagnosis were censored. 
The categories of antihypertensive drug treatment considered 
were ACE inhibitors alone, angiotensin receptor blockers 
alone, BBs alone, dihydropyridine CCBs alone, nondihydro-
pyridine CCBs alone, thiazide diuretic agents alone, a com-
bination of medications from any 2 antihypertensive classes, 
and a combination of medications from 3 or more antihy-
pertensive classes. In a separate model, individuals who were 
taking any subclass of CCBs were pooled into a single cat-
egory. Adjustment was made for age, sex, body mass index, 
Townsend Deprivation Index, smoking status, previous cancer 
diagnosis, number of noncancer diagnoses, and number of 
previous surgical operations. Individuals with a diagnosis of 




The genes and enhancer and promoter regions cor-
responding to the targets of each antihypertensive 
drug class are shown in Table II in the online-only Data 
Supplement. There was 1 gene identified for each drug 
target for ACE inhibitors (ACE), angiotensin receptor 
blockers (AGTR1), BBs (ADRB1), and thiazide diuretic 
agents (SLC12A3), and 11 genes for CCBs (CACNA1D, 
CACNA1F, CACNA2D1, CACNA2D2, CACNA1S, CAC-
NB1, CACNB2, CACNB3, CACNB4, CACNG1, and CAC-
NA1C) encoding the different calcium channel subunits 
related to effects on blood pressure. The CACNA1F 
gene is located on the X chromosome, and SNPs cor-
responding to this region were not available. Using the 
predefined selection criteria, there was 1 SNP identified 
for ACE inhibitors, 6 for BBs, and 24 for CCBs (Tables 
III through V in the online-only Data Supplement). The 
larger number of SNPs and correspondingly greater 
proportion of variation in SBP explained for CCBs was 
related to the availability of more genes from which to 
identify variants. The F statistic for SNPs ranged from 
54 to 534 (Tables III through V in the online-only Data 
Supplement), consistent with a low risk of weak instru-
ment bias.12
Mendelian Randomization
To allow comparison with RCT meta-analysis effect 
estimates, MR results for each drug class were scaled 
to their respective SBP-lowering effect in these stud-
ies. Thus, for ACE inhibitors, MR estimates are given 
per 21.14 mm Hg decrease, for BBs per 9.51 mm Hg 
decrease, and for CCBs per 8.90 mm Hg decrease.3 MR 
analysis using the single genetic variant identified for 
ACE inhibitors showed a protective effect on stroke (rel-
ative risk [RR], 0.21; 95% CI, 0.06–0.72; P=0.01) but 
not CHD risk (RR, 0.67; 95% CI, 0.16–2.56; P=0.58). 
The main MR analysis using the 6 variants for BBs iden-
tified a protective effect on CHD risk (RR, 0.62; 95% CI, 
0.47–0.81; P=4×10−4) but not stroke risk (RR, 0.91; 95% 
CI, 0.73–1.14; P=0.41). For CCBs, the main MR analysis 
using the 24 SNPs identified a protective effect on both 
CHD risk (RR, 0.73; 95% CI, 0.64–0.84; P=6×10−6) and 
stroke risk (RR, 0.75; 95% CI, 0.66–0.84; P=1×10−6). 
Similar results for all drug classes were obtained when 
the incidence of CHD and stroke was considered to be 
1%, 5%, and 10% (Table VI in the online-only Data 
Supplement). The MR estimates had overlapping 95% 
CIs to those from RCTs of these drugs versus placebo3 
(Figure 1). Individual MR estimates for each BB and CCB 
SNP are given in Figures I through IV in the online-only 
Data Supplement. Consistent MR results were found in 
sensitivity analyses, as detailed in the online-only Data 
Supplement (Results, Tables VII through IX, and Figures 
V through VIII).
Phenome-Wide Association Study
After quality control and mapping of International 
Classification of Diseases, 9th Revision and 10th Revi-
sion, to phecodes, data for 424 439 individuals across 
909 distinct phenotypes were available for PheWAS 
analysis. Details of the number of phenotypes and cas-
es per disease category are provided in the Table, with 
the number of cases and controls for each outcome in 
Tables X through XVI in the online-only Data Supple-
ment. Using the ACE inhibitor, BB, and CCB standard-
ized GRS, the respective PheWAS analyses revealed 
associations with hypertension and related cardiovas-
cular disease (Figures 2–4 and Tables X through XII in 
the online-only Data Supplement). CCBs additionally 
showed an association with higher risk of diverticu-
losis (odds ratio per SD increase in standardized GRS, 
1.02; 95% CI, 1.01–1.04, P=2×10−4). Similar results 
were obtained in PheWAS sensitivity analyses (Tables 
XIII through XVI in the online-only Data Supplement 
). Random sampling of 24 SBP SNPs from throughout 
the genome (Table I in the online-only Data Supple-
ment) to create standardized GRSs and measurement 
of associations with diverticulosis risk in permutation 
analyses (N=1000) showed effect estimates centered 
close to the null (mean odds ratio per SD increase in 
standardized GRS, 1.00; 95% CI, 0.98–1.02, P=0.79; 
Figure IX in the online-only Data Supplement). Of the 
1000 permutation analyses, only 10 had a consistent 
direction of effect and P value lower than that ob-
served for the association of the standardized CCB 
GRS with diverticulosis in PheWAS, thus generating 
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Data for 45 517 individuals were available in BioVU 
to further investigate novel PheWAS findings for traits 
unrelated to hypertension. General cohort characteris-
tics for the considered populations from the UK Bio-
bank and BioVU are detailed in Table XVII in the online-
only Data Supplement. The prevalence of diverticulosis 
in BioVU was 12%, comparable to the 10% observed 
in the UK Biobank. In BioVU, the CCB standardized GRS 
association with diverticulosis had an odds ratio per SD 
increase of 1.01 (95% CI, 1.00–1.02; P=0.17). The 
meta-analyses of UK Biobank and BioVU estimates had 
an odds ratio of 1.02 (95% CI, 1.01–1.03; P=3×10−4; 
Figure 5).
Observational Analysis of Drug Use
For the observational analysis of antihypertensive drug 
use in the UK Biobank, there were 1408 incident di-
verticulosis diagnoses up to February 13, 2016, in the 
54 612 individuals taking any of the considered antihy-
pertensive drug classes at recruitment (March 13, 2006, 
to October 1, 2010), with a mean follow-up of 2538 
days. In adjusted Cox regression (with use of thiazide 
diuretic antihypertensive medications alone as the ref-
erence category), there was no evidence for an associa-
tion between use of any CCB and risk of diverticulosis 
(hazard ratio, 1.10; 95% CI, 0.88–1.35; P=0.43). Con-
sidering CCB subclasses, there was evidence for an as-
sociation with risk of diverticulosis for nondihydropyri-
dine CCB use (hazard ratio, 1.49; 95% CI, 1.03–2.14; 
P=0.03) but not dihydropyridine CCB use (hazard ratio, 
1.01; 95% CI, 0.80–1.28; P=0.91) or any other antihy-
pertensive drug class (Table XVIII in the online-only Data 
Supplement).
DISCUSSION
This work leveraged large-scale GWAS data from 
>750 000 individuals and generated genetic proxies 
for the effect of ACE inhibitors, BBs, and CCBs, 3 of 
the most commonly used medications worldwide. The 
MR estimates for risk of CHD and stroke were compa-
rable to those observed in RCTs against placebo, which 
supports the validity of the approach. PheWAS on 909 
outcomes corroborated the known efficacy of these 
agents in preventing hypertension and related vascular 
diseases, thus further supporting the robustness of the 
genetic variants used.
The PheWAS investigation also revealed an increased 
risk of diverticulosis associated with the standardized 
Figure 1. MR estimates for the effect of genetically lower systolic blood pressure through the ACE inhibitor, β-blocker, and calcium channel blocker 
variants, respectively, on risk of coronary heart disease and stroke, compared with randomized, controlled trial meta-analysis results.3  
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GRS for CCBs. No significant association with diverticu-
losis risk was identified when SBP SNPs were explored 
more generally, which makes effects through systemic 
SBP lowering unlikely to account for this. A consistent as-
sociation between the standardized CCB GRS and diver-
ticulosis risk was found in BioVU, which contained fewer 
cases and had a correspondingly wider CI that crossed 
the null. The finding was further supported by observa-
Table. Number of Phenotypes and Cases per Disease Category in the UK Biobank Phenome-Wide Association Study Analysis
Disease Category Phenotypes, n
Cases, n
Minimum Median Mean Maximum
Circulatory system 98 202 1048 6308 133 749
Congenital anomalies 19 211 442 557 1823
Dermatologic 43 218 799 4765 82 669
Digestive 116 228 1455 4817 79 488
Endocrine/metabolic 49 208 773 4076 45 303
Genitourinary 106 203 1376 4153 103 829
Hematopoietic 22 201 569 2690 12 759
Infectious diseases 25 219 1012 2237 10 752
Injuries and poisonings 59 222 536 1513 16 683
Mental disorders 36 202 710 3280 29 405
Musculoskeletal 57 213 925 4164 53 823
Neoplasms 82 215 1124 4261 90 826
Neurological 44 204 567 2286 40 703
Pregnancy complications 17 208 1113 1854 9534
Respiratory 56 200 1124 3837 62 168
Sense organs 64 210 774 2443 39 998
Symptoms 16 304 2341 7036 42 311
Figure 2. Phenome-wide association study of the standardized genetic risk score for angiotensin-converting enzyme inhibitors. 
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tional analysis suggesting that nondihydropyridine CCB 
treatment at baseline in the UK Biobank was associated 
with increased risk of diverticulosis. Dihydropyridine and 
nondihydropyridine CCBs have different pharmacologi-
cal effects, and it also follows that their side effect pro-
files vary.22 In terms of a possible mechanism, constipa-
tion is an established side effect of nondihydropyridine 
CCBs, related to their role in reducing bowel contractil-
ity,23 and it may be through a similar process that the 
risk of diverticulosis is increased. Alternatively, there may 
be specific effects on the vasa recta vessels that pene-
trate the muscle layer of the colon, thus giving rise to 
weak points where diverticulae consequently form.24 
Complications related to diverticulosis are a common 
reason for hospital admission25 and have a rising inci-
dence.26 Given that more than one-tenth of the world’s 
adults have hypertension, and CCBs are recommended 
as a first-line pharmacological agent, with nondihydro-
pyridine drugs in particular recommended for individuals 
with concurrent atrial fibrillation,1,6 the clinical implica-
tions of these findings merit consideration. For example, 
individuals with or at increased risk of developing diver-
ticulosis might benefit from alternative pharmacologi-
cal treatments for hypertension. The genetic proxies for 
ACE inhibitors, BBs, and CCBs did not show detrimen-
tal associations with any of the other traits examined in 
PheWAS. Although absence of evidence is not evidence 
of absence, this does provide some assurance that long-
term pharmacological inhibition of these drug targets is 
generally safe, with other side effects that require hospi-
talization being smaller or rarer.
A major strength of our work is that it uses genetic 
variants to investigate the effect of antihypertensive 
drugs using existing data obtained from large-scale 
studies, thus avoiding the time and resource constraints 
associated with such study through RCTs4 and over-
coming the limitations of potential confounding and 
reverse causation from use of standard observational 
methods.7 A range of sensitivity analyses supported 
the robustness of this approach, with PheWAS allow-
ing rapid investigation of hundreds of clinically relevant 
traits across the phenome. Additionally, observational 
analysis allowed for consideration of CCB subclasses 
and further replication of novel findings.
Concerning the limitations of the study, the MR and 
PheWAS results estimate the cumulative effect of life-
long exposure to genetic variants, rather than the con-
sequence of a clinical intervention. Furthermore, there 
may be unknown pleiotropic effects of the genetic 
variants that bias the association estimates.16 Although 
less stringent criteria for selecting instruments (such as 
a more relaxed P value threshold for association with 
SBP, or a more lenient LD criterion for clumping) might 
have increased the number of variants available, this 
could also have reduced the sensitivity and specificity 
of the analysis because of the introduction of weak 
Figure 3. Phenome-wide association study of the standardized genetic risk score for β-blockers. 
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instrument bias and invalid instruments, respective-
ly. Similarly, information on gene expression was not 
incorporated in this work, and although such an ap-
proach could offer an additional strategy for identifying 
genetic variants that serve as proxies for drug effects,7 
this would be restricted to the cells or tissues in which 
gene expression was measured, limiting applicability 
for exploration of general side effects or repurposing 
opportunities. Although the PheWAS analysis was per-
formed to explore clinically relevant outcomes identi-
fied using harmonized Hospital Episode Statistics data 
in UK Biobank participants, there is also the potential 
to extend this approach to other cohorts and summary-
level genetic data.15 Finally, although the observational 
analysis of drug use in the UK Biobank did support an 
association between nondihydropyridine CCB use and 
risk of diverticulosis, it is not clear whether this find-
ing may in part relate to ascertainment bias or residual 
confounding. Diverticulosis can be incidental in asymp-
tomatic individuals, and as such, increased interaction 
with healthcare services could lead to a greater chance 
of diagnosis.
In conclusion, this work has identified genetic vari-
ants that serve as proxies for the effect of the ACE in-
Figure 4. Phenome-wide association study of the standardized genetic risk score for calcium channel blockers. 
The horizontal line depicts the 5% false-discovery rate threshold.
Figure 5. Estimates for genetic association 
between calcium channel blockers and 
diverticulosis risk derived from PheWAS 
analyses in the UK Biobank and BioVU, 
respectively, and their fixed-effects pooled 
estimate.  
BioVU indicates Vanderbilt University Bio-
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hibitor, BB, and CCB classes of antihypertensive medi-
cation. In MR and PheWAS, our instrumental variable 
approaches corroborated the established associations 
of these agents with a range of traits related to hy-
pertension. Additionally, this study identified an appar-
ent, previously unreported detrimental effect of nondi-
hydropyridine CCBs on risk of diverticulosis, a finding 
that requires further replication before it should alter 
clinical practice. No other potential side effects of any 
drug class were identified to suggest a lack of long-
term safety. This study demonstrates that the use of 
genetic variants offers a powerful complement to exist-
ing RCT and observational approaches for investigating 
the efficacy, side effects, and repurposing potential of 
antihypertensive agents.
ARTICLE INFORMATION
Received November 9, 2018; accepted May 2, 2019.
The online-only Data Supplement is available with this article at https://
www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.038814.
Correspondence
Dipender Gill, MD, Department of Biostatistics and Epidemiology, School of 
Public Health, St Mary’s Hospital, Norfolk Place, Imperial College London, Unit-
ed Kingdom, W2 1PG. Email dipender.gill@imperial.ac.uk
Affiliations
Department of Epidemiology and Biostatistics, School of Public Health, Impe-
rial College London, United Kingdom (D.G., P.E., E.E., A.D., I.T.). Institute for 
Stroke and Dementia Research, University Hospital (M.K.G., R.M., M.D.) and 
Graduate School for Systemic Neurosciences (M.K.G.), Ludwig-Maximilians-
Universität LMU, Munich, Germany. Department of Hygiene and Epidemiol-
ogy, University of Ioannina Medical School, Greece (F.K., E.E., I.T.). Division of 
Clinical Pharmacology, Department of Medicine (L.J., Q.F.) and Department of 
Biomedical Informatics (W.-Q.W., J.C.D.), Vanderbilt University Medical Center, 
Nashville, TN. Centre for Global Health Research, Usher Institute of Popula-
tion Health Sciences and Informatics, University of Edinburgh, United Kingdom 
(E.T.). Medical Research Council-Public Health England Centre for Environment, 
School of Public Health, Imperial College London, United Kingdom (P.E., A.D., 
I.T.). Imperial Biomedical Research Centre, Imperial College London and Impe-
rial College NHS Healthcare Trust, UK (P.E.). UK Dementia Research Institute at 
Imperial College London, UK (P.E., A.D., I.T.). Health Data Research UK-London 
(P.E.). Munich Cluster for Systems Neurology (SyNergy), Germany (M.D.). Ger-
man Center for Neurodegenerative Diseases (DZNE, Munich), Germany (M.D.).
Acknowledgments
D.G., M.K.G., M.D., and I.T. designed the study. D.G., M.K.G., F.K., and L.J. 
collectively had full access to the data and performed the analysis. All authors 
interpreted the results. D.G. and I.T. drafted the manuscript. All authors criti-
cally revised the manuscript for intellectual content. All authors approved the 
submitted version and are accountable for the integrity of the work.
Sources of Funding
This work was funded by the Wellcome 4i Clinical PhD Program at Imperial Col-
lege London (to D.G.); scholarships from the Deutscher Akademischer Austaus-
chdienst and the Onassis Foundation (to M.K.G.); National Institute of Health 
grants R01 HL133786, R01 GM120523 and R01 LM010685 (to Q.F., W.-Q.W., 
and J.C.D.); Cancer Research UK grants C31250/A22804 (to E.T.); the Medical 
Research Council and Public Health England (grant MR/L01341X/1) (to P.E., as 
part of the Medical Research Council-Public Health England Centre for Environ-
ment and Health); the National Institute for Health Research Imperial Biomedical 
Research Centre in collaboration with Imperial College Healthcare National Health 
Service Trust (to P.E.); the UK Medical Research Council, Alzheimer’s Society and 
Alzheimer’s Research UK (to P.E., as part of the UK Dementia Research Institute); 
a consortium led by the UK Medical Research Council (to P.E., as associate di-
rector of Health Data Research UK); the European Union Horizon 2020 research 
and innovation programme “Small vessel diseases in a mechanistic perspective: 
Targets for Intervention” (SVDs@target, No 666881; to M.D.); the German Re-
search Foundation (DFG) as part of the “Munich Cluster for Systems Neurology” 




 1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, 
Alexander L, Estep K, Hassen Abate K, Akinyemiju TF, Ali R, Alvis-Guzman N, 
Azzopardi P, Banerjee A, Bärnighausen T, Basu A, Bekele T, Bennett DA, 
Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, 
Gebru AA, Gona P, Gupta R, Hankey GJ, Jonas JB, Judd SE, Khang YH, 
Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, 
Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, 
Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, 
Rai RK, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, 
Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, 
Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, 
Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, Zaki ME, 
Murray CJ. Global burden of hypertension and systolic blood pressure of 
at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165–182. doi: 
10.1001/jama.2016.19043
 2. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, 
Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention 
of cardiovascular disease and death: a systematic review and meta-analy-
sis. Lancet. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8
 3. Wright JM, Musini VM, Gill R. First-line drugs for hypertension.  
Cochrane Database Syst Rev. 2018;4:CD001841. doi: 10.1002/14651858. 
CD001841.pub3
 4. Frieden TR. Evidence for health decision making - beyond random-
ized, controlled trials. N Engl J Med. 2017;377:465–475. doi: 10.1056/ 
NEJMra1614394
 5. Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically 
significant differences in adverse event rates in randomized controlled trials. 
J Clin Epidemiol. 2009;62:609–616. doi: 10.1016/j.jclinepi.2008.08.005
 6. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, 
Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, 
Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, 
Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, 
Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members. 2018 
ESC/ESH guidelines for the management of arterial hypertension: the Task 
Force for the management of arterial hypertension of the European Soci-
ety of Cardiology and the European Society of Hypertension. J Hypertens. 
2018;36:1953–2041. doi: 10.1097/HJH.0000000000001940
 7. Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian random-
ization: a novel approach for the prediction of adverse drug events and 
drug repurposing opportunities. Int J Epidemiol. 2017;46:2078–2089. 
doi: 10.1093/ije/dyx207
 8. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, 
Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico 
drug discovery and exploration. Nucleic Acids Res. 2006;34(database 
issue):D668–D672. doi: 10.1093/nar/gkj067
 9. Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, 
Rosen N, Kohn A, Twik M, Safran M, Lancet D, Cohen D. GeneHancer: 
genome-wide integration of enhancers and target genes in GeneCards. 
Database. 2017;2017:bax028. doi: 10.1093/database/bax028
 10. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, 
Gao H, Ntritsos G, Dimou N, Cabrera CP, Karaman I, Ng FL, Evangelou M, 
Witkowska K, Tzanis E, Hellwege JN, Giri A, Velez Edwards DR, Sun YV, 
Cho K, Gaziano JM, Wilson PWF, Tsao PS, Kovesdy CP, Esko T, Mägi R, 
Milani L, Almgren P, Boutin T, Debette S, Ding J, Giulianini F, Holliday EG, 
Jackson AU, Li-Gao R, Lin WY, Luan J, Mangino M, Oldmeadow C, 
Prins BP, Qian Y, Sargurupremraj M, Shah N, Surendran P, Thériault S, 
Verweij N, Willems SM, Zhao JH, Amouyel P, Connell J, de Mutsert R, 
Doney ASF, Farrall M, Menni C, Morris AD, Noordam R, Paré G, Poulter NR, 




 http://ahajournals.org by on July 4, 2019
Gill et al Use of Genetic Variants to Inform on Drug Effects














Barbieri CM, Batini C, Bis JC, Blake T, Bochud M, Boehnke M, Boerwinkle E, 
Boomsma DI, Bottinger EP, Braund PS, Brumat M, Campbell A, Campbell H, 
Chakravarti A, Chambers JC, Chauhan G, Ciullo M, Cocca M, Collins F, 
Cordell HJ, Davies G, de Borst MH, de Geus EJ, Deary IJ, Deelen J, Del Greco M F, 
Demirkale CY, Dörr M, Ehret GB, Elosua R, Enroth S, Erzurumluoglu AM, 
Ferreira T, Frånberg M, Franco OH, Gandin I, Gasparini P, Giedraitis V, 
Gieger C, Girotto G, Goel A, Gow AJ, Gudnason V, Guo X, Gyllensten U, 
Hamsten A, Harris TB, Harris SE, Hartman CA, Havulinna AS, Hicks AA, 
Hofer E, Hofman A, Hottenga JJ, Huffman JE, Hwang SJ, Ingelsson E, James A, 
Jansen R, Jarvelin MR, Joehanes R, Johansson Å, Johnson AD, Joshi PK, 
Jousilahti P, Jukema JW, Jula A, Kähönen M, Kathiresan S, Keavney BD, 
Khaw KT, Knekt P, Knight J, Kolcic I, Kooner JS, Koskinen S, Kristiansson K, 
Kutalik Z, Laan M, Larson M, Launer LJ, Lehne B, Lehtimäki T, Liewald DCM, 
Lin L, Lind L, Lindgren CM, Liu Y, Loos RJF, Lopez LM, Lu Y, Lyytikäinen LP, 
Mahajan A, Mamasoula C, Marrugat J, Marten J, Milaneschi Y, Morgan A, 
Morris AP, Morrison AC, Munson PJ, Nalls MA, Nandakumar P, Nelson CP, 
Niiranen T, Nolte IM, Nutile T, Oldehinkel AJ, Oostra BA, O’Reilly PF, Org E, 
Padmanabhan S, Palmas W, Palotie A, Pattie A, Penninx BWJH, Perola M, 
Peters A, Polasek O, Pramstaller PP, Nguyen QT, Raitakari OT, Ren M, Rettig R, 
Rice K, Ridker PM, Ried JS, Riese H, Ripatti S, Robino A, Rose LM, Rotter JI, 
Rudan I, Ruggiero D, Saba Y, Sala CF, Salomaa V, Samani NJ, Sarin AP, 
Schmidt R, Schmidt H, Shrine N, Siscovick D, Smith AV, Snieder H, Sõber S, 
Sorice R, Starr JM, Stott DJ, Strachan DP, Strawbridge RJ, Sundström J, 
Swertz MA, Taylor KD, Teumer A, Tobin MD, Tomaszewski M, Toniolo D, 
Traglia M, Trompet S, Tuomilehto J, Tzourio C, Uitterlinden AG, Vaez A, 
van der Most PJ, van Duijn CM, Vergnaud AC, Verwoert GC, Vitart V, 
Völker U, Vollenweider P, Vuckovic D, Watkins H, Wild SH, Willemsen G, 
Wilson JF, Wright AF, Yao J, Zemunik T, Zhang W, Attia JR, Butterworth AS, 
Chasman DI, Conen D, Cucca F, Danesh J, Hayward C, Howson JMM, Laakso M, 
Lakatta EG, Langenberg C, Melander O, Mook-Kanamori DO, Palmer CNA, 
Risch L, Scott RA, Scott RJ, Sever P, Spector TD, van der Harst P, Wareham NJ, 
Zeggini E, Levy D, Munroe PB, Newton-Cheh C, Brown MJ, Metspalu A, 
Hung AM, O’Donnell CJ, Edwards TL, Psaty BM, Tzoulaki I, Barnes MR, 
Wain LV, Elliott P, Caulfield MJ; Million Veteran Program. Genetic analysis of 
over 1 million people identifies 535 new loci associated with blood pressure 
traits. Nat Genet. 2018;50:1412–1425. doi: 10.1038/s41588-018-0205-x
 11. Churchhouse C, Neale B. Rapid GWAS of thousands of phenotypes for 
337,000 samples in the UK Biobank. Neale Lab web site. http://www.
nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-
337000-samples-in-the-uk-biobank. Published July 19, 2017. Accessed 
March 30, 2018.
 12. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, 
Davey Smith G, Sterne JA. Using multiple genetic variants as instrumental 
variables for modifiable risk factors. Stat Methods Med Res. 2012;21:223–
242. doi: 10.1177/0962280210394459
 13. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, 
Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, Webb TR, Zeng L, Dehghan A, 
Alver M, Armasu SM, Auro K, Bjonnes A, Chasman DI, Chen S, Ford I, 
Franceschini N, Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim YK, 
Kleber ME, Lau KW, Lu X, Lu Y, Lyytikäinen LP, Mihailov E, Morrison AC, 
Pervjakova N, Qu L, Rose LM, Salfati E, Saxena R, Scholz M, Smith AV, 
Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao W, de Andrade M, 
de Vries PS, van Zuydam NR, Anand SS, Bertram L, Beutner F, Dedoussis G, 
Frossard P, Gauguier D, Goodall AH, Gottesman O, Haber M, Han BG, Huang J, 
Jalilzadeh S, Kessler T, König IR, Lannfelt L, Lieb W, Lind L, Lindgren CM, 
Lokki ML, Magnusson PK, Mallick NH, Mehra N, Meitinger T, Memon FU, 
Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis LS, Rasheed A, 
Samuel M, Shah SH, Sinisalo J, Stirrups KE, Trompet S, Wang L, Zaman KS, 
Ardissino D, Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, Chambers JC, 
Collins R, Cupples LA, Danesh J, Demuth I, Elosua R, Epstein SE, Esko T, 
Feitosa MF, Franco OH, Franzosi MG, Granger CB, Gu D, Gudnason V, 
Hall AS, Hamsten A, Harris TB, Hazen SL, Hengstenberg C, Hofman A, 
Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, Kim BJ, Kooner JS, 
Kullo IJ, Lehtimäki T, Loos RJF, Melander O, Metspalu A, März W, Palmer CN, 
Perola M, Quertermous T, Rader DJ, Ridker PM, Ripatti S, Roberts R, 
Salomaa V, Sanghera DK, Schwartz SM, Seedorf U, Stewart AF, Stott DJ, 
Thiery J, Zalloua PA, O’Donnell CJ, Reilly MP, Assimes TL, Thompson JR, 
Erdmann J, Clarke R, Watkins H, Kathiresan S, McPherson R, Deloukas P, 
Schunkert H, Samani NJ, Farrall M. A comprehensive 1,000 Genomes-
based genome-wide association meta-analysis of coronary artery disease. 
Nat Genet. 2015;47:1121–1130. doi: 10.1038/ng.3396
 14. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, 
Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, Anderson CD, 
Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, 
Benavente OR, Bevan S, Boncoraglio GB, Brown RD Jr, Butterworth AS, 
Carrera C, Carty CL, Chasman DI, Chen WM, Cole JW, Correa A, 
Cotlarciuc I, Cruchaga C, Danesh J, de Bakker PIW, DeStefano AL, 
den Hoed M, Duan Q, Engelter ST, Falcone GJ, Gottesman RF, Grewal RP, 
Gudnason V, Gustafsson S, Haessler J, Harris TB, Hassan A, Havulinna AS, 
Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, 
Ingelsson E, Irvin MR, Jian X, Jiménez-Conde J, Johnson JA, Jukema JW, 
Kanai M, Keene KL, Kissela BM, Kleindorfer DO, Kooperberg C, Kubo M, 
Lange LA, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, 
Leys D, Lewis CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, 
Maguire J, Manichaikul A, McArdle PF, Meschia JF, Mitchell BD, Mosley 
TH, Nalls MA, Ninomiya T, O’Donnell MJ, Psaty BM, Pulit SL, Rannikmäe K, 
Reiner AP, Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, 
Rotter JI, Rundek T, Sacco RL, Sakaue S, Sale MM, Salomaa V, Sapkota BR, 
Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow CLM, 
Tanislav C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, 
Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, van Duijn CM, Walters M, 
Wareham NJ, Wassertheil-Smoller S, Wilson JG, Wiggins KL, Yang Q, 
Yusuf S, Bis JC, Pastinen T, Ruusalepp A, Schadt EE, Koplev S, 
Björkegren JLM, Codoni V, Civelek M, Smith NL, Trégouët DA, 
Christophersen IE, Roselli C, Lubitz SA, Ellinor PT, Tai ES, Kooner JS, Kato N, 
He J, van der Harst P, Elliott P, Chambers JC, Takeuchi F, Johnson AD, 
Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, 
Longstreth WT Jr, Rolfs A, Hata J, Woo D, Rosand J, Pare G, Hopewell JC, 
Saleheen D, Stefansson K, Worrall BB, Kittner SJ, Seshadri S, Fornage M, 
Markus HS, Howson JMM, Kamatani Y, Debette S, Dichgans M, Malik R, 
Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, 
Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, Anderson CD, 
Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, 
Benavente OR, Bevan S, Boncoraglio GB, Brown RD Jr, Butterworth AS, 
Carrera C, Carty CL, Chasman DI, Chen WM, Cole JW, Correa A, 
Cotlarciuc I, Cruchaga C, Danesh J, de Bakker PIW, DeStefano AL, 
Hoed MD, Duan Q, Engelter ST, Falcone GJ, Gottesman RF, Grewal RP, 
Gudnason V, Gustafsson S, Haessler J, Harris TB, Hassan A, Havulinna AS, 
Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, 
Ingelsson E, Irvin MR, Jian X, Jiménez-Conde J, Johnson JA, Jukema JW, 
Kanai M, Keene KL, Kissela BM, Kleindorfer DO, Kooperberg C, Kubo M, 
Lange LA, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, 
Leys D, Lewis CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, 
Maguire J, Manichaikul A, McArdle PF, Meschia JF, Mitchell BD, Mosley TH, 
Nalls MA, Ninomiya T, O’Donnell MJ, Psaty BM, Pulit SL, Rannikmäe K, 
Reiner AP, Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, 
Rotter JI, Rundek T, Sacco RL, Sakaue S, Sale MM, Salomaa V, Sapkota BR, 
Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow CLM, 
Tanislav C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, 
Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, van Duijn CM, Walters M, 
Wareham NJ, Wassertheil-Smoller S, Wilson JG, Wiggins KL, Yang Q, 
Yusuf S, Amin N, Aparicio HS, Arnett DK, Attia J, Beiser AS, Berr C, 
Buring JE, Bustamante M, Caso V, Cheng YC, Choi SH, Chowhan A, 
Cullell N, Dartigues JF, Delavaran H, Delgado P, Dörr M, Engström G, Ford I, 
Gurpreet WS, Hamsten A, Heitsch L, Hozawa A, Ibanez L, Ilinca A, 
Ingelsson M, Iwasaki M, Jackson RD, Jood K, Jousilahti P, Kaffashian S, 
Kalra L, Kamouchi M, Kitazono T, Kjartansson O, Kloss M, Koudstaal PJ, 
Krupinski J, Labovitz DL, Laurie CC, Levi CR, Li L, Lind L, Lindgren CM, 
Lioutas V, Liu YM, Lopez OL, Makoto H, Martinez-Majander N, Matsuda K, 
Minegishi N, Montaner J, Morris AP, Muiño E, Müller-Nurasyid M, 
Norrving B, Ogishima S, Parati EA, Peddareddygari LR, Pedersen NL, Pera J, 
Perola M, Pezzini A, Pileggi S, Rabionet R, Riba-Llena I, Ribasés M, 
Romero JR, Roquer J, Rudd AG, Sarin AP, Sarju R, Sarnowski C, Sasaki M, 
Satizabal CL, Satoh M, Sattar N, Sawada N, Sibolt G, Sigurdsson Á, 
Smith A, Sobue K, Soriano-Tárraga C, Stanne T, Stine OC, Stott DJ, 
Strauch K, Takai T, Tanaka H, Tanno K, Teumer A, Tomppo L, Torres-Aguila NP, 
Touze E, Tsugane S, Uitterlinden AG, Valdimarsson EM, van der Lee SJ, 
Völzke H, Wakai K, Weir D, Williams SR, Wolfe CDA, Wong Q, Xu H, 
Yamaji T, Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, 
Longstreth WT Jr, Rolfs A, Hata J, Woo D, Rosand J, Pare G, Hopewell JC, 
Saleheen D, Stefansson K, Worrall BB, Kittner SJ, Seshadri S, Fornage M, 
Markus HS, Howson JMM, Kamatani Y, Debette S, Dichgans M; AFGen 
Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiol-
ogy (CHARGE) Consortium; International Genomics of Blood Pressure 
(iGEN-BP) Consortium; INVENT Consortium; STARNET; BioBank Japan Co-
operative Hospital Group; COMPASS Consortium; EPIC-CVD Consortium; 
EPIC-InterAct Consortium; International Stroke Genetics Consortium 




 http://ahajournals.org by on July 4, 2019
Gill et al Use of Genetic Variants to Inform on Drug Effects
Circulation. 2019;140:00–00. DOI: 10.1161/CIRCULATIONAHA.118.038814 xxx xxx, 2019 11
ORIGINAL RESEARCH 
ARTICLE
CHARGE Consortium; NINDS Stroke Genetics Network (SiGN); UK Young 
Lacunar DNA Study; MEGASTROKE Consortium; MEGASTROKE Consor-
tium:. Multiancestry genome-wide association study of 520,000 subjects 
identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 
2018;50:524–537. doi: 10.1038/s41588-018-0058-3
 15. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, Paul DS, 
Freitag D, Burgess S, Danesh J, Young R, Butterworth AS. PhenoScanner: 
a database of human genotype-phenotype associations. Bioinformatics. 
2016;32:3207–3209. doi: 10.1093/bioinformatics/btw373
 16. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analy-
ses for robust causal inference from Mendelian randomization analy-
ses with multiple genetic variants. Epidemiology. 2017;28:30–42. doi: 
10.1097/EDE.0000000000000559
 17. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, 
Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, 
Young A, Sprosen T, Peakman T, Collins R. UK Biobank: an open ac-
cess resource for identifying the causes of a wide range of complex 
diseases of middle and old age. PLoS Med. 2015;12:e1001779. doi: 
10.1371/journal.pmed.1001779
 18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, 
Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for 
whole-genome association and population-based linkage analyses. Am J 
Hum Genet. 2007;81:559–575. doi: 10.1086/519795
 19. Li X, Meng X, Spiliopoulou A, Timofeeva M, Wei WQ, Gifford A, 
Shen X, He Y, Varley T, McKeigue P, Tzoulaki I, Wright AF, Joshi P, 
Denny JC, Campbell H, Theodoratou E. MR-PheWAS: exploring the causal 
effect of SUA level on multiple disease outcomes by using genetic in-
struments in UK Biobank. Ann Rheum Dis. 2018;77:1039–1047. doi: 
10.1136/annrheumdis-2017-212534
 20. Verma A, Bradford Y, Dudek S, Lucas AM, Verma SS, Pendergrass SA, 
Ritchie MD. A simulation study investigating power estimates in phe-
nome-wide association studies. BMC Bioinformatics. 2018;19:120. doi: 
10.1186/s12859-018-2135-0
 21. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, 
Pulley JM, Ramirez AH, Bowton E, Basford MA, Carrell DS, Peissig PL, 
Kho AN, Pacheco JA, Rasmussen LV, Crosslin DR, Crane PK, Pathak J, 
Bielinski SJ, Pendergrass SA, Xu H, Hindorff LA, Li R, Manolio TA, Chute CG, 
Chisholm RL, Larson EB, Jarvik GP, Brilliant MH, McCarty CA, Kullo IJ, 
Haines JL, Crawford DC, Masys DR, Roden DM. Systematic comparison 
of phenome-wide association study of electronic medical record data and 
genome-wide association study data. Nat Biotechnol. 2013;31:1102–
1110. doi: 10.1038/nbt.2749
 22. Frishman WH. Calcium channel blockers: differences between sub-
classes. Am J Cardiovasc Drugs. 2007;7(suppl 1):17–23. doi: 10.2165/ 
00129784-200707001-00003
 23. Morris CR, Harvey IM, Stebbings WS, Speakman CT, Kennedy HJ, Hart AR. 
Do calcium channel blockers and antimuscarinics protect against perforat-
ed colonic diverticular disease? A case control study. Gut. 2003;52:1734–
1737. doi: 10.1136/gut.52.12.1734
 24. Brian West A. The pathology of diverticulosis: classical concepts and mu-
cosal changes in diverticula. J Clin Gastroenterol. 2006;40 Suppl 3:S126–
S131. doi: 10.1097/01.mcg.0000225508.90417.07
 25. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part 
II: lower gastrointestinal diseases. Gastroenterology. 2009;136:741–754. 
doi: 10.1053/j.gastro.2009.01.015
 26. Etzioni DA, Mack TM, Beart RW Jr, Kaiser AM. Diverticulitis in the United 
States: 1998-2005: changing patterns of disease and treatment. Ann 




 http://ahajournals.org by on July 4, 2019
